This article is more than 5 years old. Information may no longer be current.
High-dose vitamin D improved bone health in HIV patients on tenofovir
Click Here to Manage Email Alerts
Significant monthly doses of vitamin D decreased hormonal changes that lead to bone loss among HIV patients assigned tenofovir, according to an NIH press release.
“What we’ve found suggests vitamin D could be used to counteract one of the major concerns about using tenofovir to treat HIV,” said Rohan Hazra, MD, of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. “People in their teens and 20s may be on anti-HIV treatment for decades to come, so finding a safe and inexpensive way to protect their long-term bone health would be a major advance.”
The study included 200 participants aged 18 to 25 years assigned tenofovir or other forms of anti-HIV treatment. Participants were administered a monthly 50,000-unit dose of vitamin D or placebo. The recommended daily dose of vitamin D is 600 units.
At the end of 3 months, researchers observed a 14% decrease in parathyroid hormone levels among participants assigned tenofovir, whereas no decrease was observed among those assigned other types of anti-HIV therapies.
No adverse effects from vitamin D were observed.
A follow-up study will be conducted to examine the long-term safety of vitamin D in a similar group of HIV-infected youth assigned antiretroviral regimens containing tenofovir and to determine whether the changes in parathyroid hormone result in improvements in bone density, according to the press release.
 |
Follow InfectiousDiseaseNews.com on Twitter. |